EN | RU
EN | RU

Help Support

Back

Ubrogepant shows similar efficacy in perimenstrual and non-perimenstrual migraine attacks

Ubrogepant Ubrogepant
Ubrogepant Ubrogepant

What's new?

With a favorable safety profile, Ubrogepant exhibits comparable effectiveness for the management of both perimenstrual and non-perimenstrual migraines.

A post hoc analysis depicted that Ubrogepant, an oral calcitonin gene-related peptide receptor antagonist, exhibits comparable efficacy in addressing both perimenstrual migraine (pmM) and non-pmM attacks. Additionally, no new safety issues were observed. Investigators aimed to assess the effectiveness and safety of Ubrogepant in treating pmM attacks.

Following completion of one of two phase 3 trials, subjects had the option to join a 52-week, open-label, phase 3, long-term safety extension trial. In this trial, they were re-randomized to one of three groups: standard care, Ubrogepant 50 mg, or Ubrogepant 100 mg, with an equal distribution (1:1:1). This study focused on evaluating the effectiveness of Ubrogepant in a specific subgroup of females who used Ubrogepant to treat at least one pmM or non-pmM attack.

A pmM attack was defined as occurring between two days prior and the initial three days of menstrual bleeding. The study reported the mean (standard deviation [SD]) of Ubrogepant-treated attacks that achieved 2-hour pain freedom and pain relief, with equal weight given to each volunteer's outcomes. Out of a total of 734 women in the modified intent-to-treat group, 354 women reported experiencing at least one menstrual cycle during which they also had a headache treated with Ubrogepant.

Among these, 278 women reported pmM attacks, and 716 reported non-pmM attacks. Pain relief within 2 hours was observed in a mean (SD) of 28.7% (37.4) of pmM attacks and 22.1% (26.9) of non-pmM when treated with a 50 mg dose of Ubrogepant. For the 100 mg dose, the percentages were 29.7% (35.2) for pmM attacks and 25.3% (26.3) for non-pmM attacks.

There was no considerable variation in the mean percentage of pmM and non-pmM attacks that attained 2-hour pain alleviation with either 100 mg (67.1% [37.4] vs. 68.4% [30.2]) or 50 mg (64.8% [39.9] vs. 65.2% [32.4]) of Ubrogepant. In the pmM subgroup, treatment-related adverse events occurred in 8.8% (12 out of 137) of individuals receiving the 50 mg dose and 12.8% (18 out of 141) of those receiving the 100 mg dose of Ubrogepant. Thus, Ubrogepant displayed comparable effectiveness in treating both pmM and non-pmM attacks, and there were no new safety concerns identified.

Source:

Headache

Article:

Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis

Authors:

E Anne MacGregor et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: